1. Aringhieri S, Carli M, Kolachalam S, Verdesca V, Cini E, Rossi M, et al. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. Pharmacol Ther 2018; 192: 20-41.
2.
Blair HA. Lumateperone: First approval. Drugs 2020; 80(4): 417-23.
3.
CAPLYTA demonstrated safety in 2,664 adult patients with schizophrenia and bipolar depression. 2022. [https://www.caplytahcp.com/schizophrenia/safety/adverse-reactions] (last access 21.02.2023).
4.
Chen J, Stringer R, Shah B, Gu J, Zhang Y, Hackling M, et al. Drug-Drug Interaction Studies to Evaluate the Effect of Inhibition of UGT1A1 and CYP3A4 and Induction of CYP3A4 on the Pharmacokinetics of Tropifexor in Healthy Subjects. Clin Pharmacol Drug Dev 2022; (11): 1253-63.
5.
Correll CU. From receptor pharmacology to improved outcomes: Individualising the selection, dosing, and switching of antipsychotics 2010; 25(suppl. 2): 12-21.
6.
Correll CU, Davis RE, Weingart M, Saillard J, O’Gorman C, Kane JM, et al. Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry 2020; 77(4): 349-58.
7.
Correll CU, Vanover KE, Davis RE, Chen R, Satlin A, Mates S. Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia. Schizophr Res 2021; 228: 198-205.
8.
D’Souza I, Durgam S, Satlin A, Davis RE, Kozauer SG, Chen R, et al. Lumateperone (ITI−007) in the Treatment of Bipolar Depression: Results from a Randomized Clinical Trial. CNS Spectrums. Cambridge University Press 2021; 26(2): 150.
9.
Davis R, Correll CU. ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. Expert Review of Neuroterapheutics 2016; 16(6): 601-14.
10.
Davis R, Hendrick JP, Zhang L, Yao W, Wennogle LP, Zhu H, et al. The novel Pharmacology of ITI-007 is enhanced and extended by its metabolic back conversion from IC200131. Schizophrenia Research 2014; 153, #S78.
11.
Davis R, Dmitrienko A, Glass S, Kozauer S, Saillard J, Weingart M, et al. Lumateperone (ITI-007): favorable safety profile in an open label safety switching study from standard-of-care antipsychotic therapy in patients with schizophrenia. Schizophr Bull 2018; 44(Suppl1): S236-S237.
12.
Davis R, Saillard J. Safety and tolerability of ITI-007 in patients with dementia: a novel treatment designed to treat behavioral disturbances associated with dementia and related disorders. J Prev Alzheimers Dis 2014; 1(3): 287-88.
13.
Edinoff A, Wu N, deBoisblanc C, Feltner CO, Norder M, Tzoneva V, et al. Lumateperone for the Treatment of Schizophrenia. Psychopharmacol Bull 2020; 50(4): 32-59.
14.
FDA Label. Lumateperone Drug Prescribing and Safety Information [https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf]. (last access 21.02.2023).
15.
Greenwood J, Acharya RB, Marcellus V, Rey JA. Lumateperone: A novel antipsychotic for schizophrenia. Ann Pharmacother 2021; 55(1): 98-104.
16.
Hussar DA. New Drugs 2021, Part 1. Nursing. 2021; 51: 36-44.
17.
Intra-Cellular Therapies. Caplyta (lumateperone) capsules, for oral use: US prescribing information. 2019. [http://www.acces sdata.fda.gov/] (last access 21.02.2023).
18.
Kane JM, Vanover KE, Durgam S, Weingart M, Davis R, Satlin A, et al. Efficacy and safety of lumateperone tosylate 42 mg in the treatment of schizophrenia: A pooled analysis of phase 2 and 3 studies. Eur Neuropsychopharmacol 2019; 29, S453-S454.
19.
Kantrowitz JT. The Potential Role of Lumateperone-Something Borrowed? Something New? JAMA Psychiatry 2020; 77(4): 343-344.
20.
Lee G, Zhou Y. NMDAR Hypofunction Animal Models of Schizophrenia. Front Mol Neurosci 2019; 12: 185.
21.
Lieberman JA, Davis RE, Correll CU, Goff DC, Kane JM, Tamminga CA, et al. ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. Biol Psychiatry 2016; 79(12): 952-61.
22.
McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry 2020; 19(1): 15-33.
23.
Mosiołek A, Objawy pozapiramidowe w psychiatrii – diagnostyka i leczenie, Psychiatria 2014; 11(3): 160-5.
24.
Rejestr Badań Klinicznych UE [https://www.clinicaltrialsregister.eu/ctr-search/search?query=lumateperone] (last access 27.03.2023).
25.
Satlin A, Vanover KE, Durgam S, Mates S, Davis RE, Correll C. Additional results from a 12-month open-label safety study of lumateperone (ITI-007) in patients with stable symptoms of schizophrenia. 32nd annual Psych Congress, Oct. 3-6, 2019, San Diego, California. [poster 129 - https://www.hmpgloballearningnetwork.com/site/pcn/posters/results-12-month-open-label-safety-study-lumateperone-iti-007-patients-stable-symptoms] (last access 21.02.2023).
26.
Snyder GL, Vanover KE, Zhu H, Miller DB, O’Callaghan JP, Tomesch J, et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology (Berl) 2015; 232(3): 605-21.
27.
Syed AB, Brašić JR. The role of lumateperone in the treatment of schizophrenia. Ther Adv Psychopharmacol 2021, 11: 20451253211034019.
28.
Titulaer J, Radhe O, Danielsson K, Dutheil S, Marcus MM, Jardemark K, et al. Lumateperone – mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: A dopamine D1 receptor dependent mechanism. Eur Neuropsychopharmacol 2022; 62: 22-35.
29.
Vanover KE, Staner L, Luthringer R, Mates S, Davis RE. ITI-007/ITI-722: a new approach for the treatment of sleep maintenance insomnia and sleep disorders associated with psychiatric and neurological diseases. Sleep 2009; 32(Suppl S): 284-5.
30.
Vanover KE, Davis RE, Zhou Y, Ye W, Brašić JR, Gapasin L., et al. Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia. Neuropsychopharmacology 2019; 44(3): 598-605.
31.
Vyas P, Hwang BJ, Brašić JR. An evaluation of lumateperone tosylate for the treatment of schizophrenia. Expert Opin Pharmacother 2020, 21(2): 139-45.
